Investigating the effects of integrase inhibitors during pregnancy on child development
Official title: Integrase Inhibitors during pregnancy and Neurodevelopmental Outcomes: Underlying Mechanism and Therapeutic Intervention
Funded at University of Nebraska Medical Center · NIH-11089494 · Data updated 2026-11-12
This study is looking at how the medication Dolutegravir, which some pregnant women take for HIV, might affect the development of their children, and it aims to find ways to make this medicine safer for both moms and their babies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $573,445 |
| NIH project number | 5R01HD115482-02 |
| Project ID | NIH-11089494 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include pregnant women who are HIV-positive and are considering or currently using Dolutegravir as part of their treatment regimen.
✕Less likely to help
Patients who are not pregnant or who do not have HIV may not receive any benefit from this research.
What this research studies
This research focuses on understanding how the antiretroviral drug Dolutegravir (DTG) affects neurodevelopment in children born to mothers who take this medication during pregnancy. The study aims to uncover the mechanisms behind any potential developmental issues and explore therapeutic interventions to make DTG safer for use in pregnant women. By examining both prenatal and postnatal effects, the research seeks to fill critical knowledge gaps regarding the safety of DTG for mothers and their children. Patients may be involved in assessments that evaluate the impact of DTG on child development.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for pregnant women with HIV, ultimately improving developmental outcomes for their children.
How similar studies have gone: While there is ongoing research into the effects of antiretroviral drugs during pregnancy, this specific investigation into DTG's neurodevelopmental impact is relatively novel.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Bade, Aditya N — University of Nebraska Medical Center
- Study coordinator: Bade, Aditya N
Related research
Other NIH-funded projects on the same topics.
-
How air pollution during pregnancy affects fetal growth over time
This study looks at how air pollution affects the growth of babies in the womb during pregnancy, using ultrasound images to track changes over time, and it aims to help expectant parents understand when their babies might be most at risk from pollution.
-
Postoperative Pain Guidelines for Pregnancy: Safer, Patient-Centered Opioid Use
We’re creating patient-friendly guidelines to help doctors manage pain after delivery and surgery in pregnant people, aiming to reduce opioid overuse and improve safety.
-
HPV and pregnancy risk: a big study following 1,280 pregnancies
A large pregnancy study at UTMB looks at whether human papillomavirus (HPV) during pregnancy is linked to problems like preterm birth.
-
Understanding how where you live and personal factors during pregnancy affect a child’s risk for obesity and metabolic problems
This project looks at how neighborhood conditions and individual factors during pregnancy may influence a child’s risk of obesity and metabolic health as they grow.
-
Blocking cancer-causing cMYC tricks after pregnancy changes in the breast
Researchers are testing how pregnancy and aging reshape the breast before cancer risk, using patient-reinformed models to see if it changes how dangerous cMYC signals behave.
-
SSRI use during pregnancy: effects on placental blood flow and inflammation
This grant studies how antidepressants (SSRIs) used during pregnancy might affect the placenta and inflammation, and whether a 5-HT2 receptor blocker could mitigate any negative effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.